RT Journal Article
SR Electronic
T1 Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2294
OP 2297
VO 28
IS 10
A1 T Yamamoto
A1 Y Moriwaki
A1 S Takahashi
A1 Z Tsutsumi
A1 T Hada
YR 2001
UL http://www.jrheum.org/content/28/10/2294.abstract
AB OBJECTIVE: To investigate whether fenofibrate increases the clearance of purine bases (hypoxanthine, xanthine, uric acid) and oxypurinol. METHODS: We administered fenofibrate (150 mg) 3 times a day for 3 days, and then allopurinol (300 mg) 4 h after the last administration of fenofibrate, to 5 healthy subjects. Ten hours later, a clearance study was done. RESULTS: Following 3 day administration of fenofibrate, fractional clearance of xanthine, uric acid, and oxypurinol increased by 41% (p < 0.05), 101% (p < 0.01), and 51% (p < 0.01), respectively, compared to baseline values, while the respective plasma concentrations decreased by 46% (p < 0.05), 46% (p < 0.05), and 19% (p < 0.05). CONCLUSION: Our results suggest that fenofibrate, fenofibric acid, or fenofibrate derivatives can increase fractional clearance of xanthine, uric acid, and oxypurinol by acting on their common renal pathways. It is suggested that the hypouricemic effect of combination therapy using allopurinol and fenofibrate may be less than additive.